Top

Published in:

01-11-2021 | Pancreatic Tumors

Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer

Authors: Asmita Chopra, MBBS, Mazen Zenati, MD, Melissa E. Hogg, MD, Herbert J. Zeh III, MD, David L. Bartlett, MD, Nathan Bahary, MD, Amer H. Zureikat, MD, Joal D. Beane, MD

Published in: Annals of Surgical Oncology | Issue 12/2021

Abstract

Introduction

A positive microscopic margin (R1) following resection of pancreatic ductal adenocarcinoma (PDAC) can occur in up to 80% of patients and is associated with reduced survival and increased recurrence. Our aim was to characterize the impact of neoadjuvant therapy (NAT) on survival and recurrence in patients with PDAC following an R1 resection.

Methods

A retrospective analysis of patients with PDAC who underwent pancreatectomy from 2008 to 2017 was performed. Patients were staged according to the American Joint Committee on Cancer 8th edition and stratified based on resection margin (R0 vs. R1) and treatment sequence (NAT vs. surgery first [SF]). Conditional survival analysis was performed using Cox regression and inverse probability weighted estimates.

Results

Among 580 patients, 59% received NAT and 41% underwent SF. On final pathology, the NAT cohort had smaller tumors and less lymph node (LN) positivity (p < 0.05). NAT was not associated with an R1 resection (50%, p = 0.653). Compared with the R1 cohort, the R0 cohort had a higher median overall survival (OS; 39.6 vs. 22.8 months; hazard ratio [HR] 1.6, p < 0.001) and disease-free survival (DFS; 19 vs. 13 months; HR 1.35, p = 0.004). After risk adjustment, NAT was not associated with OS, regardless of margin status (R0, 95% confidence interval [CI] (−)7.31–27.07, p = 0.26; or R1, 95% CI (−)36.99–15.25, p = 0.42). However, NAT was associated with improved DFS in the R1 cohort (95% CI 1.79–11.91, p = 0.008) but not in the R0 cohort (95% CI (−)11.22–10.54, p = 0.95).

Conclusion

An R0 resection remains an important determinant of overall and disease-free survival, even when NAT is administered. For patients with an R1 resection, receipt of NAT may prolong DFS.

Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. (eds). SEER Cancer Statistics Review, 1975–2016, National Cancer Institute. Bethesda, MD. Available at https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019.

Groot VP, Gemenetzis G, Blair AB, et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg. 2019;269(6):1154–62. https://doi.org/10.1097/SLA.0000000000002734.CrossRefPubMed

Ghaneh P, Kleeff J, Halloran CM, et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg. 2019;269(3):520–9. https://doi.org/10.1097/SLA.0000000000002557.CrossRefPubMed

Nitta T, Nakamura T, Mitsuhashi T, et al. The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Surg Today. 2017;47(4):490–7. https://doi.org/10.1007/s00595-016-1420-7.CrossRefPubMed

Kurlinkus B, Ahola R, Zwart E, et al. In the era of the leeds protocol: a systematic review and a meta-analysis on the effect of resection margins on survival among pancreatic ductal adenocarcinoma patients. Scand J Surg. 2020;109(1):11–7. https://doi.org/10.1177/1457496920911807.CrossRefPubMed

The Royal College of Pathologists. Standards and minimum datasets for reporting cancers. Minimum dataset for the histopathological reporting of pancreatic, ampulla of Vater and bile duct carcinoma. London: The Royal College of Pathologists; 2002.

Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers. Ann Surg Oncol. 2018;25(4):845–7. https://doi.org/10.1245/s10434-017-6025-x.CrossRefPubMed

Nagakawa Y, Sahara Y, Hosokawa Y, et al. Clinical impact of neoadjuvant chemotherapy and chemoradiotherapy in borderline resectable pancreatic cancer: analysis of 884 patients at facilities specializing in pancreatic surgery. Ann Surg Oncol. 2019;26(6):1629–36. https://doi.org/10.1245/s10434-018-07131-8.CrossRefPubMed

Youngwirth LM, Nussbaum DP, Thomas S, et al. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: an analysis of 18243 patients. J Surg Oncol. 2017;116(2):127–32. https://doi.org/10.1002/jso.24630.CrossRefPubMed

10.

Al Abbas AI, Zenati M, Reiser CJ, et al. Serum CA19-9 response to neoadjuvant therapy predicts tumor size reduction and survival in pancreatic adenocarcinoma. Ann Surg Oncol. 2020;27:2007–14. https://doi.org/10.1245/s10434-019-08156-3.CrossRefPubMedPubMedCentral

11.

Zhan HX, Xu JW, Wu D, et al. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Cancer Med. 2017;6(6):1201–19. https://doi.org/10.1002/cam4.1071.CrossRefPubMedPubMedCentral

12.

Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–73. https://doi.org/10.1200/JCO.19.02274.CrossRefPubMedPubMedCentral

13.

Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(7):963–9. https://doi.org/10.1001/jamaoncol.2018.0329.CrossRefPubMedPubMedCentral

14.

Cloyd JM, Heh V, Pawlik TM et al. Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials. J Clin Med. 2020;9(4). pii:E1129. https://doi.org/10.3390/jcm9041129.

15.

Schorn S, Demir IE, Reyes CM, et al. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Cancer Treat Rev. 2017;55:96–106. https://doi.org/10.1016/j.ctrv.2017.03.003.CrossRefPubMed

16.

Sugimoto M, Takahashi N, Farnell MB, et al. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: a propensity matching and intention-to-treat analysis. J Surg Oncol. 2019;120(6):976–84. https://doi.org/10.1002/jso.25681.CrossRefPubMed

17.

Lee AJ, Simoneau E, Chiang YJ, et al. Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing. HPB (Oxford). 2019;21(9):1203–10. https://doi.org/10.1016/j.hpb.2019.01.011.CrossRefPubMed

18.

Beane JD, Zenati M, Hamad A, Hogg ME, Zeh HJ, Zureikat AH. Robotic pancreatoduodenectomy with vascular resection: outcomes and learning curve. Surgery. 2019;166(1):8–14. https://doi.org/10.1016/j.surg.2019.01.037.CrossRefPubMed

19.

National Comprehensive Cancer Network. Pancreatic cancer (Version 1.2020). Available at: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed 26 Feb 2020

20.

Strobel O, Hank T, Hinz U, et al. Pancreatic cancer surgery: the new R-status counts. Ann Surg. 2017;265(3):565–73. https://doi.org/10.1097/SLA.0000000000001731.CrossRefPubMed

21.

Hank T, Hinz U, Tarantino I, et al. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. Br J Surg. 2018;105(9):1171–81. https://doi.org/10.1002/bjs.10842.CrossRefPubMed

22.

You Y, Choi DW, Heo JS, et al. Clinical significance of revised microscopic positive resection margin status in ductal adenocarcinoma of pancreatic head. Ann Surg Treat Res. 2019;96(1):19–26. https://doi.org/10.4174/astr.2019.96.1.19.CrossRefPubMed

23.

Konstantinidis IT, Warshaw AL, Allen JN, et al. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a ‘true’ R0 resection? Ann Surg. 2013;257(4):731–6. https://doi.org/10.1097/SLA.0b013e318263da2f.CrossRefPubMed

24.

Gebauer F, Tachezy M, Vashist YK, et al. Resection margin clearance in pancreatic cancer after implementation of the Leeds Pathology Protocol (LEEPP): clinically relevant or just academic? World J Surg. 2015;39(2):493–9. https://doi.org/10.1007/s00268-014-2808-4.CrossRefPubMed

25.

Lai CC, Wang SY, Liao CH et al. Surgical margin status of patients with pancreatic ductal adenocarcinoma undergoing surgery with radical intent: risk factors for the survival impact of positive margins. In Vivo. 2018;32(6):1591–1597. https://doi.org/10.21873/invivo.11419.

26.

Vega EA, Kutlu OC, Salehi O, et al. Preoperative chemotherapy for pancreatic cancer improves survival and r0 rate even in early stage I. J Gastrointest Surg. 2020;24(10):2409–15. https://doi.org/10.1007/s11605-020-04601-x.CrossRefPubMed

27.

Osipov A, Nissen N, Rutgers J, et al. Redefining the positive margin in pancreatic cancer: impact on patterns of failure, long-term survival and adjuvant therapy. Ann Surg Oncol. 2017;24(12):3674–82. https://doi.org/10.1245/s10434-017-6076-z.CrossRefPubMed

28.

Suss NR, Talamonti MS, Bryan DS, et al. Does adjuvant radiation provide any survival benefit after an R1 resections for pancreatic cancer? Surgery. 2018;163(5):1047–52. https://doi.org/10.1016/j.surg.2017.09.022.CrossRefPubMed

29.

Bernard ME, Sutera PA, Iarrobino NA, et al. Initial results of a prospective study of adjuvant pancreatic stereotactic body radiation therapy for close or positive margins. Adv Radiat Oncol. 2018;4(2):294–301. https://doi.org/10.1016/j.adro.2018.11.007.CrossRefPubMedPubMedCentral

30.

Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24. https://doi.org/10.1016/S0140-6736(16)32409-6.CrossRefPubMed

31.

Wu W, He J, Cameron JL, et al. The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol. 2014;21(9):2873–81. https://doi.org/10.1245/s10434-014-3722-6.CrossRefPubMedPubMedCentral

32.

Kimbrough CW, Hill CR, Martin RCG, McMasters KM, Scoggins CR. Tumor-positive resection margins reflect an aggressive tumor biology in pancreatic cancer. J Surg Oncol. 2013;107(6):602–7. https://doi.org/10.1002/jso.23299.CrossRefPubMed

33.

Schorn S, Demir IE, Samm N, et al. Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. BJS Open. 2018;2(2):52–61. https://doi.org/10.1002/bjs5.46.CrossRefPubMedPubMedCentral

Title: Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer
Authors: Asmita Chopra, MBBS
Mazen Zenati, MD
Melissa E. Hogg, MD
Herbert J. Zeh III, MD
David L. Bartlett, MD
Nathan Bahary, MD
Amer H. Zureikat, MD
Joal D. Beane, MD
Publication date: 01-11-2021
Publisher: Springer International Publishing
Published in: Annals of Surgical Oncology / Issue 12/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-021-10175-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2021

ASO Author Reflections: Predicting Postoperative Resolution of Hypertension in Primary Hyperaldosteronism

Enhanced Recovery After Surgery can Improve Patient Outcomes and Reduce Hospital Cost of Gastrectomy for Cancer in the West: A Propensity-Score-Based Analysis

ASO Author Reflection: Is There a Role for Cardiopulmonary Exercise Testing Before Esophagectomy?

ASO Author Reflections: Prediction of Survival Outcomes Based on Preoperative Clinical Parameters in Gastric Cancer

Clinical Significance of Serum Squamous Cell Carcinoma Antigen for Patients with Recurrent Esophageal Squamous Cell Carcinoma

Impact of Residential Racial Integration on Postoperative Outcomes Among Medicare Beneficiaries Undergoing Resection for Cancer